Search research articles
Contact Us
Filters
Showing results (251-260 of 299) with videos related to
Page
of 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Investigational New Drugs
|
April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Investigational New Drugs
|
March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C Smith, Thea Kalebic, Jeffrey R Infante, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Lancet (London, England)
|
May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Journal for Immunotherapy of Cancer
|
October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Andrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Cancer
|
July 17, 2015
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
Johanna C Bendell, Robin K Kelley, Kent C Shih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E G Chiorean, D D Von Hoff, M Reni, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 299) with videos related to
Sort By:
Page
of 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Investigational New Drugs
|
April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Investigational New Drugs
|
March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C Smith, Thea Kalebic, Jeffrey R Infante, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Lancet (London, England)
|
May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Journal for Immunotherapy of Cancer
|
October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Andrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Cancer
|
July 17, 2015
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
Johanna C Bendell, Robin K Kelley, Kent C Shih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E G Chiorean, D D Von Hoff, M Reni, et al.
Page
of 30